Calico and AbbVie form an R&D partnership on aging and age-related diseases such as neurodegeneration and cancer

Calico

AbbVie and Calico formed an R&D collaboration to discover, develop and market therapies for age-related diseases including neurodegeneration and cancer. The partnership committed up to $1.5 billion total investment ($250M each initially, plus $500M potential from each), with Calico handling early development through Phase 2a over ten years and AbbVie commercializing afterward.

• Up to $1.5 billion total commitment: $250M each initially, plus $500M potential from both parties.
• Calico leads discovery and development through Phase 2a (10 years); AbbVie takes over for Phase 2a onward.
• Costs and profits split equally throughout collaboration.
• Enabled Calico to establish major research facility in San Francisco Bay Area.